SCHEMBL6049581

SCHEMBL6049581

Nc1nc(N)c(-c2cc(Cl)cc(Cl)c2Cl)c(C(Cl)(Cl)Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 6/20 0.44
SCN9A Q15858 4/20 0.37
SCN3A Q9NY46 4/20 0.37
SCN10A Q9Y5Y9 4/20 0.37
SCN5A Q14524 2/20 0.37
KCNH2 Q12809 2/20 0.37
SCN1A P35498 1/20 0.37
KCNK2 O95069 1/20 0.36
HTR2B P41595 2/20 0.36
PDE4D Q08499 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP2D6 P10635 2/20 0.36
ADRA1A P35348 2/20 0.36
MAOA P21397 1/20 0.36
MAPK1 P28482 1/20 0.36
SCN4A P35499 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
PDE3A Q14432 1/20 0.36
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL170312 0.86 SCN2A (0.43) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL5070133 0.78 SCN2A (0.46) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL136398 0.74 HEXA (0.43) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL6049518 0.74 SCN2A (0.43) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL6049636 0.71 CYP2D6 (0.51) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL5070785 0.71 HEXA (0.43) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL7389114 0.70 SCN2A (0.53) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL5070759 0.70 SCN9A (0.50) SCN2ASCN9ASCN3ASCN10ASCN5A
SCHEMBL6049467 0.70 HTR2B (0.51) SCN10AKCNH2HTR2BPDE4DSMN1; SMN2
SCHEMBL7387066 0.70 SCN2A (0.49) SCN2ASCN9ASCN3ASCN10ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1681058-A2 Pharmacologically active cns compounds THE WELLCOME FOUNDATION LIMITED (GB) 2006-07-19 EP disclosed
EP-1325916-A1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system THE WELLCOME FOUNDATION LIMITED (GB) 2003-07-09 EP disclosed
US-5712276-A TREATING NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. (US) 1998-01-27 US disclosed
US-5684005-A PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE GLAXO WELLCOME INC. (US) 1997-11-04 US disclosed
US-5635507-A PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER GLAXO WELLCOME INC. (US) 1997-06-03 US disclosed
US-5597827-A CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. 1997-01-28 US disclosed
US-5591746-A GLUTAMATE INHIBITORS; CENTRAL NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. 1997-01-07 US disclosed
US-5587380-A ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. (US) 1996-12-24 US disclosed
EP-0727213-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727214-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727212-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0715851-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-06-12 EP disclosed
EP-0713703-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-05-29 EP disclosed
CN-1117046-A Method for preparing pharmaceutically active CNS compounds WELLCOME FOUND (GB) 1996-02-21 CN disclosed
US-5136080-A Intermediates for glutamate inhibitors BURROUGHS WELLCOME CO. (US) 1992-08-04 US disclosed
EP-0372934-A2 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-13 EP disclosed